GLS Capital’s Jamison Lynch and Dr. Lauren Rabinovic published in the Jan./Feb. issue of American Pharmaceutical Review

Over the past several years, litigation funding has emerged as a strategic tool for pharmaceutical and biotechnology companies navigating the complex terrain of intellectual property litigation. As the industry continues to evolve, the dynamics and evaluation criteria for litigation funding will play an increasingly important role in shaping the legal strategies of companies seeking to protect their intellectual property or to challenge the intellectual property of its competitors.


In early February, GLS Capital’s Jamison Lynch and Dr. Lauren Rabinovic were published in the Jan./Feb. issue of American Pharmaceutical Review, where they explored the fundamentals, evaluation criteria, and benefits of litigation funding for pharma and biotech companies involved in intellectual property disputes.

In the article, the authors discuss the use and benefits of litigation funding as a strategy to mitigate the high costs associated with litigation, the basics of how funding arrangements work, and analyze the increasing utilization by pharma and biotech companies to enforce their patents against alleged infringers.

The article also goes in-depth into the recent emergence of using capital as a strategic tool for defendants in Hatch-Waxman litigation. Jamie and Lauren go through the various challenges faced in bringing litigation in the pharmaceutical sector, the differences in approach to litigation in the pharmaceutical industry compared to other industries, and the impact of funding on the industry. They also touch on the use of medical litigation funding and the potential ethical and legal issues associated.

According to its website, American Pharmaceutical Review is the leading review journal for business and technology in the pharmaceutical industry throughout North America since 1998. Published seven times a year, APR provides unbiased editorials on topics such as drug delivery, information technology, research & development, analytical development and control, equipment and facility manufacturing, and regulatory affairs. Each issue offers American Pharmaceutical Review’s 40,000 readers of senior executives, technical personnel, scientists, and others fully abreast of the latest trends and developments in the process of pharm/biopharma manufacturing.

Read the full article in the January/February 2024 issue of
American Pharmaceutical Review

Skip to content